XBI News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

XB

Volume

11.20M

Loading chart

XB

XBIState Street SPDR S&P Biotech ETF

XBI

Pay with—

Available Balance0.00

XB

AUM

N/A

Volume

11.20M

Yield

0.38%

Chart Earnings News About Dividends Insider Filings

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?PBE is a smart beta ETF focused on biotechnology and genome companies with $412.99 million in assets. It has delivered strong year-to-date returns of 16.68% and one-year returns of 36.23%, but carries higher risk with a standard deviation of 20.18%. The fund charges a 0.59% expense ratio and holds concentrated positions in healthcare stocks like Natera, Illumina, and Biogen. Cheaper alternatives like XBI and IBB are available for investors seeking lower-cost options.Zacks Investment Research · Oct 14, 2026

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?The Invesco Biotechnology & Genome ETF (PBE) is a passively managed fund with $418.99 million in assets, offering exposure to the Healthcare-Biotech sector. With a 0.59% expense ratio and 1.38% dividend yield, it returned 18.51% over the past year but carries higher risk with a beta of 0.70 and 20.16% standard deviation. The fund holds 33 concentrated positions with top holdings including Royalty Pharma, Gilead Sciences, and Biogen. PBE received a Zacks ETF Rank of 3 (Hold), with larger competitors XBI and IBB offering lower expense ratios.Zacks Investment Research · Oct 13, 2026

Should You Invest in the VanEck Biotech ETF (BBH)?The VanEck Biotech ETF (BBH) offers low-cost exposure to the biotech sector with a 0.35% expense ratio and $462.7 million in assets. The fund tracks the MVIS US Listed Biotech 25 Index and holds 26 companies with top holdings including Amgen, Gilead Sciences, and Vertex Pharmaceuticals. BBH has returned 21.89% year-to-date and 39.46% over the past year, but carries higher risk with a beta of 0.70 and 19.89% standard deviation. The fund received a Zacks ETF Rank of 2 (Buy).Zacks Investment Research · Sep 16, 2026

PVG Sends Open Letter to Anavex Stockholders Detailing the Need for Change at the CompanyPVG Asset Management, a significant shareholder of Anavex Life Sciences, has launched a proxy contest calling for complete board reconstitution, citing operational failures, governance issues, and failure to deliver shareholder value. PVG has nominated six biotechnology-experienced directors to replace the current board, criticizing the company's underperformance relative to peers, delayed clinical trials for its lead drug blarcamesine, significant executive departures, and recent stock decline amid broader biotech sector gains.GlobeNewswire Inc. · Sep 3, 2026

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?The First Trust NYSE Arca Biotechnology ETF (FBT) is a passively managed fund offering broad exposure to the biotech sector with $2.91 billion in assets. The ETF has delivered strong performance with 29.36% gains year-to-date and 55.34% over the past year, though it carries higher risk with a beta of 0.66 and 20.71% standard deviation. With a 0.55% expense ratio and a Zacks ETF Rank of 2 (Buy), FBT is positioned as a solid option for biotech exposure, though larger competitors like IBB and XBI offer lower expense ratios.Zacks Investment Research · Sep 1, 2026

Breakfast News: A Conversation With Ionis CEOIonis Pharmaceuticals CEO Brett Monia discusses the company's progress in 2026, highlighting FDA approval for Tryngolza and upcoming results for Pelacarsen in heart disease treatment. The company targets cash flow break-even in 2028 and projects $7 billion in peak revenue from late-stage programs. With 13 neurology drugs in clinical trials, Ionis aims to establish itself as a leader in antisense technology beyond first-mover competitors.The Motley Fool · Aug 22, 2026

iShares Global Healthcare ETF vs State Street SPDR Biotech ETF. Which Healthcare-Focused Fund Will Bring You Profits in 2026 and Beyond?The article compares two healthcare-focused ETFs: iShares Global Healthcare ETF (IXJ) and State Street SPDR S&P Biotech ETF (XBI). XBI delivered superior 1-year returns of 80.2% with small-cap biotech focus but carries higher volatility (54% max drawdown). IXJ offers more stability with lower volatility, higher dividend yield (1.4%), and international diversification across large-cap pharmaceutical and healthcare companies. The analysis recommends XBI for long-term investors prioritizing performance despite greater risk.The Motley Fool · Aug 8, 2026

Fidelity Health Care vs. State Street Biotech: Which ETF Fits Your Portfolio Best?The Fidelity MSCI Health Care Index ETF (FHLC) offers broad healthcare sector exposure with lower costs (0.08% expense ratio), higher dividend yield (1.3%), and lower volatility, making it suitable for conservative investors. The State Street SPDR S&P Biotech ETF (XBI) focuses on biotechnology with higher growth potential (89.3% 1-year return) but carries significantly higher risk (54% maximum drawdown) and costs (0.35% expense ratio), appealing to aggressive investors.The Motley Fool · Jul 5, 2026

Healthcare: Pockets of AlphaThe healthcare sector, down 3.8% year-to-date and the worst performer among S&P 500 sectors, presents selective opportunities despite weak aggregate earnings growth. While the sector faces headwinds with the lowest forward profit margins and weakest 2026 EPS growth outlook, specific subsectors show promise: Pharmaceuticals are rerating as GLP-1 economics mature, Biotech benefits from M&A activity, and smaller-cap healthcare companies outperform large-cap peers. The recommendation is a market-weight position focusing on areas with improving earnings, margins, and catalysts rather than broad sector exposure.Investing.com · Jun 23, 2026

VHT vs. XBI: Vanguard Health Care ETF Tops SPDR Biotech in Yield and CostThe Vanguard Health Care ETF (VHT) offers broader healthcare sector exposure with lower costs (0.09% expense ratio) and higher dividend yield (1.69%), while the SPDR S&P Biotech ETF (XBI) provides targeted biotech exposure with higher volatility but stronger recent 1-year returns (62.20% vs 13.00%). VHT is better suited for income-seeking investors seeking diversified healthcare exposure, while XBI appeals to aggressive investors seeking biotech-specific growth.The Motley Fool · May 28, 2026

to start trading

XB

XBIState Street SPDR S&P Biotech ETF

XBI

Pay with—

Available Balance0.00

Your PositionYou don't own any XBI yet.

Related Tickers

Earnings

Dividends

Last · Jun 22Quarterly

Amount$0.14

Yield0.38%

Annual$0.54